### CONTENT

**CHAPTER 1**  
Introduction  
1. General introduction and outline  

**CHAPTER 2**  
The usefulness of established AD-biomarkers with different ways of detection  
2. Discriminatory and predictive capabilities of enzyme-linked immunosorbent assay and multiplex platforms in a longitudinal Alzheimer’s disease study  
*Alzheimer’s & Dementia, 2013*  

**CHAPTER 3**  
Clusterin and ApoE as biomarkers for neurodegenerative disease, and their role in the etiology of Alzheimer’s disease  
3.1 Quantification of clusterin in paired cerebrospinal fluid and plasma samples  
*Annals of Clinical Biochemistry, 2013*  
3.2 Cerebrospinal fluid and plasma clusterin levels in Parkinson’s disease  
*Parkinsonism and Related Disorders, 2013*  
3.3 Clusterin predicts cognitive decline and progression to Alzheimer’s disease  
*Submitted*  
3.4 Clusterin is associated with Alzheimer’s disease mechanisms in non-demented individuals  
*Submitted*
CHAPTER 4

Aβ-oligomers quantification in CSF, and their clinical value

4.1 Amyloid-β oligomer detection by ELISA in cerebrospinal fluid and brain tissue
   *Analytical Biochemistry, 2013*

4.2 Amyloid-β oligomers relate to cognitive decline in Alzheimer’s disease
   *Submitted*

CHAPTER 5

Discussion

5. General discussion and suggestions for future research

APPENDIX

Nederlandse samenvatting

Dankwoord

Curriculum Vitae